This content is only available to 2022 ASCRS Annual Meeting phyisican registrants
To log in, click the teal "Login" button in the upper right-hand corner of this page. If you are logged in but still do not have access, please check your 2022 Annual Meeting registration.
Since the bioerodible, sustained-release dexamethasone intraocular suspension 9% was approved for postoperative inflammation, surgeons have been working to optimize its administration. Most recently, we have found success injecting the drug directly into the capsular bag, adjacent to the intraocular lens implant. This video will demonstrate strategies for success with intracapsular delivery.